Citation
91 FR 63569
Multiple canonical documents share this first-page citation.
- National Cancer Institute; Notice of Meeting 91 FR 63569
- Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf) 91 FR 63569
- Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications; Correction 91 FR 63569